Roadmap to Cultivate an Innovative Biologics Industry in China

  • Recommend
  • Tweet
  • Print
  • Email

Tuesday, November 12, 2013, 1:00 p.m. - 4:25 p.m., Room 402 A & B

The bio-industry has been designated as one of China’s seven strategic emerging industries (SEI) by the government. Within the bio-industry, therapeutic biologics hold significant promise for China to achieve breakthrough innovation and to address largely unmet medical needs in many disease areas. Today, China’s therapeutic biologics industry stands at RMB 18 billion, representing less than 2 percent of the global total. This panel will explore the steps that may be taken by the government and industry to develop a world-class innovative biologics sector in China.

Policy Focused Speeches:

  • International Policy Environment and Trends in the Global Biotechnology Industry
  • China Bio-industry Policies & Competencies
  • Building a World-Class Innovative Therapeutic Biologics Industry in China

Panelists:

  • James Cai, Early Clinical Development Strategy Lead for APAC, Genentech
  • Joseph Cho, Managing Director, R&D-based Pharmaceutical Association Committee (RDPAC)
  • Joseph Damond, Senior Vice President of International Affairs, BIO
  • Hongguang Wang, Advisor, Deputy Director, Chinese Academy of Science and Technology for Development (CASTED), Ministry of Science and Technology (MoST)
  • Michael Yu, CEO, Innovent Biologics